Trial Profile

Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalteparin sodium (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
Focus Therapeutic Use

Most Recent Events

01 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
23 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2015 to 1 Apr 2016.
22 May 2013 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com